|
Abstract:
Background
The Oncotype Dx testing in breast cancer is commercially available multigene expression testing to determine patients with breast cancer with potential benefit from chemotherapy and the risk of recurrence. The aim of this study was to determine the patients' selection for this type of testing.
Methods
We have collected retrospective study over period of 3 months in our breast unit in a view to collect all relevant data and determine whether the right patients has been selected for testing. The gold standard was NICE guidelines recommendation.
Results
We have collected 51 patients in total. Calculating the NPI we have been able to establish that 22 patients should have been offered Oncotype Dx testing. This was only offered to 10 patients and to 2 more patients who were not eligible according to NICE guidelines.
Conclusion
This study has shown that the compliance with NICE guidelines in our unit is quite poor. Only 43% of patients eligible and 55% of patients in total have been offered Oncotype Dx testing. It would be interesting to compare these results to other unit in the country.
Discussion
Oncotype Dx is good quality genetic testing and predictive tool for right patients. Unfortunately it does not take into account other patients' factors which may influence the outcome.
|
